Compare Abbott Laboratories (ABT) vs Hewlett Packard Enterprise Co (HPE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Hewlett Packard Enterprise Co — how do they compare? Abbott Laboratories trades at $95.14 (market cap $166.94B), while Hewlett Packard Enterprise Co trades at $44.7 (market cap $57.56B). The key difference: Abbott Laboratories is far larger — about 2.9× Hewlett Packard Enterprise Co's market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | HPE | |
|---|---|---|
Market Cap | $166.94B | $57.56B |
Sector | Health | Technology |
52-Week High | $136.62 | $56.14 |
52-Week Low | $82.57 | $19.81 |
Enterprise Value | $193.69B | $73.52B |
Dividend Yield | 2.63% | 1.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
HPE trades at $43.445, up 5.42% today, with a bearish technical signal despite recent earnings beats. Revenue grew to $34.3B in 2025, but net income fell sharply to $57M, pressuring margins. Analysts show a mixed consensus with a $69.69 price target, implying significant upside. The stock faces headwinds from high valuation multiples and volatile cash flows, though AI server demand and dividend payments offer support.
The outlook balances growth from AI infrastructure investments against execution risks and margin pressure. Upside hinges on sustained earnings outperformance and debt management, while downside risks include competitive threats and macroeconomic volatility. Institutional sentiment is cautiously optimistic given the high price target disparity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Hewlett Packard Enterprise Co
Hewlett Packard Enterprise is an information technology vendor that provides hardware and software to enterprises. Its primary product lines are compute servers, storage arrays, and networking equipment.
Read more on HPE →
